Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Mar 12, 2019 10:51am EDT

XORTX Signs LOI for Co-Development and Licensing Agreement with Japan’s Teijin Pharma Limited

Jan 28, 2019 7:00am EST

XORTX to Present at NobleConXV Noble Capital Markets’ 15th Annual Investor Conference

Nov 26, 2018 5:00pm EST

XORTX Receives FDA Response on Orphan Drug Designation Application

Nov 06, 2018 9:58pm EST

XORTX Announces Appointment of CFO

Oct 23, 2018 7:00am EDT

XORTX Announces Revision to Polycystic Kidney Disease Clinical Development Plan

Oct 15, 2018 7:00am EDT

XORTX Announces New Clinical Advisory Board Members

Sep 10, 2018 7:00am EDT

XORTX Announces Submission of Orphan Drug Designation Application

Aug 13, 2018 7:00am EDT

XORTX Submits FDA pre-IND Meeting Documents

Jun 28, 2018 8:59am EDT

XORTX Reports on Annual Special Meeting and Provides Corporate Update

Jun 08, 2018 7:00am EDT

XORTX Announces Filing of FDA pre-IND Meeting Request Letter

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • arrow_forward
rss_feed News RSS
©2023 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap